Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil
- PMID: 2354712
- DOI: 10.1007/BF01417563
Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil
Abstract
The effect of a controlled-release formulation of isosorbide-5-mononitrate (IS-5-MN) was studied in patients with coronary heart disease (CHD), with the aim of comparing the acute effect with that after chronic administration on parameters of ischemia. To determine whether any tolerance developed, several aspects of ischemia were observed: ECG signs, clinical parameters, and left ventricular function. Fifteen patients with angiographically proven CHD were examined with 12-lead exercise ECG before, 2 h and 4 h after the first dose and after 10 days of therapy with 60 mg IS-5-MN (Coleb-Duriles) once daily. After 7 days, three radionuclide ventriculographies were performed: control, 2 h after nitrate and 2 h after 75 mg gallopamil. Plasma concentrations of IS-5-MN were measured before every exercise test. The results showed a reduction of total ST-segment depression from 0.59 mV to 0.29 mV after 2 h (NS) and 4 h (P less than 0.05) on the 1st day and from 0.48 mV to 0.32 mV (P less than 0.05) and 0.31 mV (NS) after 10 days. The severity of angina pectoris was diminished by about 50%. The effect on exercise duration and time to ST-segment depression by more than 0.1 mV remained unchanged after 10 days, whereas the effect on blood pressure, heart rate and time to onset of angina was attenuated. The mean decrease in ejection fraction (EF) from rest to exercise was reduced from--5.9% to -1.9% (P less than 0.05) after nitrate, while an increase of +1.4% was seen after gallopamil (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Combined gallopamil and isosorbide-5-mononitrate in "mixed" angina pectoris.J Cardiovasc Pharmacol. 1992;20 Suppl 7:S64-70. J Cardiovasc Pharmacol. 1992. PMID: 1284159 Clinical Trial.
-
Comparison of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in a slow-release form on exercise-induced myocardial ischemia.J Clin Pharmacol. 1991 Jul;31(7):636-40. doi: 10.1002/j.1552-4604.1991.tb03749.x. J Clin Pharmacol. 1991. PMID: 1894759 Clinical Trial.
-
[Lack of tolerance development in interval therapy with 50 mg isosorbide-5-nitrate retard (Elantan long)].Z Kardiol. 1989;78 Suppl 2:72-8; discussion 115-7. Z Kardiol. 1989. PMID: 2511697 Clinical Trial. German.
-
Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.Eur Heart J. 1988 Feb;9(2):149-58. doi: 10.1093/oxfordjournals.eurheartj.a062468. Eur Heart J. 1988. PMID: 3280317 Review.
-
Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 2:S21-7; discussion S29-31. doi: 10.1097/00005344-199908002-00005. J Cardiovasc Pharmacol. 1999. PMID: 10499557 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous